VITamin D and OmegA-3 TriaL (VITAL): Effects of Vitamin D Supplements on Risk of Falls in the US Population
| Autor: | Peggy M. Cawthon, Vadim Bubes, Gregory Kotler, Elle M Murata, Meryl S. LeBoff, Sharon H. Chou, Nancy R. Cook, JoAnn E. Manson, Julie E. Buring |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Vitamin medicine.medical_specialty Endocrinology Diabetes and Metabolism primary prevention Clinical Biochemistry Population Poison control vitamin D 030204 cardiovascular system & hematology Biochemistry law.invention Fractures Bone 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Double-Blind Method Randomized controlled trial Risk Factors law Internal medicine falls Fatty Acids Omega-3 medicine Vitamin D and neurology Humans 030212 general & internal medicine education Aged Clinical Research Article education.field_of_study business.industry Biochemistry (medical) Odds ratio Middle Aged United States Vitamin D and Omega-3 Trial Treatment Outcome chemistry Dietary Supplements Accidental Falls Female business Cholecalciferol AcademicSubjects/MED00250 |
| Zdroj: | The Journal of Clinical Endocrinology and Metabolism |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/clinem/dgaa311 |
| Popis: | Context It is unclear whether vitamin D supplementation reduces risk of falls, and results from randomized controlled trials (RCTs) are conflicting. Objective The objective of this work is to determine whether 2000 IU/day of supplemental vitamin D3 decreases fall risk. Design VITamin D and OmegA-3 TriaL (VITAL) is a double-blind, placebo-controlled RCT including 25 871 adults, randomly assigned November 2011 to March 2014 and treated for 5.3 years (median). Setting This is a nationwide study. Participants Men 50 years or older and women 55 years or older (mean age, 67.1 years) without cancer or cardiovascular disease at baseline participated in this study. Interventions Interventions included vitamin D3 (cholecalciferol; 2000 IU/day) and/or omega-3 fatty acids (1 g/day) or respective placebos in a 2 × 2 factorial design. Main Outcome Measures Main outcome measures include 2 or more falls and falls resulting in a doctor or hospital visit. Results Baseline serum total 25-hydroxyvitamin D (25[OH]D) level was 77 nmol/L; characteristics were well-balanced between groups. Numbers of participants with 2 or more falls were similar between active and placebo groups (9.8% vs 9.4%). Over 5 years, there were no differences in the proportion having 2 or more falls (odds ratio [OR] = 0.97; 95% CI, 0.90-1.05, P = .50), falls resulting in a doctor visit (OR = 1.03; 95% CI, 0.94-1.13, P = .46), or resulting in a hospital visit (OR = 1.04; 95% CI, 0.90-1.19, P = .61) between groups. Results did not differ between those with baseline 25(OH)D less than 50 vs 50 nmol/L or greater or other cut points. Conclusion Daily supplemental vitamin D3 vs placebo did not decrease fall risk in generally healthy adults not selected for vitamin D insufficiency. This large RCT does not indicate that supplemental vitamin D should be used for primary prevention of falls in the US population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|